Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.

Jin ZhaoLihong LiuHao LiDan SunYi HuChen ZhangYuhui Zhang

Published in: Expert opinion on drug safety (2023)

ALK TKIs were associated with higher risks of cardiovascular toxicities. In particular, special attention should be given to the risks of cardiac disorders and VTEs related to crizotinib therapy.

Keyphrases

human health
advanced non small cell lung cancer
risk assessment
open label
double blind
working memory
clinical trial
stem cells
placebo controlled
phase iii
epidermal growth factor receptor
phase ii
randomized controlled trial
mesenchymal stem cells
chronic myeloid leukemia
tyrosine kinase